RNA Polymerase III Inhibitor

ML60218 (CAS 577784-91-9) is a broad spectrum inhibitor of RNA polymerase III fromS. Cerevisiaeas well as from human cells, IC50=32mM and 27mM respectively.1 Combined treatment with ML-60218 and an HDAC inhibitor caused augmented suppression of colony formation, induction of cell cycle arrest and apoptotic cell death in human pancreatic adenocarcinoma cells.2

ML-60218 is a broad-spectrum RNA pol III inhibitor, with IC50s of 32 and 27 μM for Saccharomyces cerevisiae and human. ML-60218 disrupts already assembled viroplasms and to hamper the formation of new ones without the need for de novo transcription of cellular RNAs[1][2].

A cell-permeable indazolo-sulfonamide compound that displays broad-spectrum inhibitory activity against RNA Polymerase III (IC₅₀ = 27 and 32 μM for human and S. cerevisiae RNA Pol III, respectively). Inhibits cell growth in yeast by preventing RNA Pol III-mediated tRNA transcription. Also available as a 25 mM solution in DMSO (Cat. No. 557404).

Product does not compete with ATP.

[1] LIPING WU. Novel small-molecule inhibitors of RNA polymerase III.[J]. Eukaryotic Cell, 2003, 2 2: 256-264. DOI:10.1128/ec.2.2.256-264.2003
[2] NELSON S YEE. Targeting developmental regulators of zebrafish exocrine pancreas as a therapeutic approach in human pancreatic cancer.[J]. Biology Open, 2012, 1 4: 295-307. DOI:10.1242/bio.2012539